Emmanuel Lacroix
Direttore/Membro del Consiglio presso Lumos Pharma Sub, Inc.
Profilo
Emmanuel works with Arix Biosciences as Venture Partner, with a focus on sourcing, executing and managing investments within Europe.
He has a broad biotech background with expertise spanning venture capital, business development, and biotech or pharma strategy and operations.
Previously, Emmanuel was Vice President and Partner at UCB Ventures.
In that role, he sourced and led equity investments in Esobiotec, Walden Biosciences and Locanabio, as well as LP investments in other funds.
Earlier, as UCB’s Head of Business Development Neurology, he executed multiple licensing agreements and product acquisitions, plus equity investments in Lumos Pharma (Nasdaq : LUMO), and he led the launch and equity financing of UCB’s spin-out Syndesi Therapeutics (acquired by AbbVie).
He also held prior leadership positions in Sales and Global Marketing, at UCB, and in Discovery Research for Gene Editing at Cellectis SA.
Emmanuel received an MBA from IMD (Switzerland), a Ph.D.
in Molecular Biology from ULB (Belgium) based on research conducted at the European Molecular Biology Laboratory (Germany), and a MSc in Biochemistry from the ULG (Belgium).
He previously served on the Boards of Esobiotec, Walden Biosciences, Syndesi Therapeutics (acquired by AbbVie), and as observer, Locanabio and Lumos (Nasdaq : LUMO).
Posizioni attive di Emmanuel Lacroix
| Società | Posizione | Inizio |
|---|---|---|
Lumos Pharma Sub, Inc.
 Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | Direttore/Membro del Consiglio | - |
UCB Ventures (Private Equity)
 UCB Ventures (Private Equity) Investment ManagersFinance UCB Ventures is the venture capital arm of UCB SA and was founded in 2016. UCB Ventures is headquartered in Brussels, Belgium with additional offices in Boston, Massachusetts and London, United Kingdom. | Investitore di Private Equity | 01/04/2017 |
Walden Biosciences, Inc.
 Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Walden Biosciences, Inc. provides renal therapeutics services. The company is headquartered in Cambridge, MA. | Direttore/Membro del Consiglio | - |
Syndesi Therapeutics SA
 Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | Direttore/Membro del Consiglio | - |
EsoBiotec SA
 EsoBiotec SA Miscellaneous Commercial ServicesCommercial Services EsoBiotec SA is a Belgian company that provides research and development on natural sciences and engineering. The company is based in Charleroi, Belgium. The company was founded in 2020 by Jean-Pierre Latere. Jean-Pierre Latere has been the CEO since 2020. | Direttore/Membro del Consiglio | 31/08/2021 |
Arix Bioscience /Venture Capital/
 Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | Investitore di Private Equity | 01/08/2022 |
Precedenti posizioni note di Emmanuel Lacroix
| Società | Posizione | Fine |
|---|---|---|
| UCB | Corporate Officer/Principal | - |
Formazione di Emmanuel Lacroix
| University of Liege | Undergraduate Degree |
| Université Libre de Bruxelles | Graduate Degree |
| IMD College | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| UCB | Health Technology |
| Aziende private | 6 |
|---|---|
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | Health Services |
UCB Ventures (Private Equity)
UCB Ventures (Private Equity) Investment ManagersFinance UCB Ventures is the venture capital arm of UCB SA and was founded in 2016. UCB Ventures is headquartered in Brussels, Belgium with additional offices in Boston, Massachusetts and London, United Kingdom. | Finance |
Walden Biosciences, Inc.
Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Walden Biosciences, Inc. provides renal therapeutics services. The company is headquartered in Cambridge, MA. | Health Services |
Syndesi Therapeutics SA
Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | Commercial Services |
EsoBiotec SA
EsoBiotec SA Miscellaneous Commercial ServicesCommercial Services EsoBiotec SA is a Belgian company that provides research and development on natural sciences and engineering. The company is based in Charleroi, Belgium. The company was founded in 2020 by Jean-Pierre Latere. Jean-Pierre Latere has been the CEO since 2020. | Commercial Services |
Arix Bioscience /Venture Capital/
Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | Finance |
- Borsa valori
- Insiders
- Emmanuel Lacroix
